Cacace Angela M 4

What Happened Angela M. Cacace, Chief Scientific Officer of Arvinas, sold 9,657 shares of ARVN on 2026-05-11 at $9.94 per share, generating total proceeds of $95,965. The filing shows this was a sale (S) and the transaction was conducted to satisfy tax withholding obligations tied to the vesting and settlement of RSUs — not a discretionary market trade.

Key Details

• Transaction date and price: 2026-05-11, 9,657 shares at $9.94 each.
• Total proceeds: $95,965.
• Shares owned after the transaction: Not disclosed in the provided filing details.
• Footnote: The sale was automatic by the issuer to cover tax withholding for one-half of RSUs granted May 9, 2025 (non-discretionary).
• Filing timeliness: Form 4 filed 2026-05-13 (appears timely; within the normal 2-business-day reporting window).

Context This was a routine "sell-to-cover" tied to RSU vesting rather than a voluntary open-market sell tied to sentiment. Such transactions are common when companies or insiders sell shares to pay taxes on vested equity and generally do not by themselves signal a change in insider conviction.